Cost-effectiveness analysis of pharmacogenetic-guided warfarin dosing in Thailand

© 2014 Elsevier Ltd. All rights reserved. Introduction Pharmacogenetic (PGx) test is a useful tool for guiding physician on an initiation of an optimal warfarin dose. To implement of such strategy, the evidence on the economic value is needed. This study aimed to determine the cost-effectiveness of...

Full description

Saved in:
Bibliographic Details
Main Authors: Chong,H., Saokaew,S., Dumrongprat,K., Permsuwan,U., Wu,D.B.C., Sritara,P., Chaiyakunapruk,N.
Format: Article
Published: Elsevier Limited 2015
Subjects:
Online Access:http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84915826535&origin=inward
http://cmuir.cmu.ac.th/handle/6653943832/38551
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Chiang Mai University
id th-cmuir.6653943832-38551
record_format dspace
spelling th-cmuir.6653943832-385512015-06-16T07:50:27Z Cost-effectiveness analysis of pharmacogenetic-guided warfarin dosing in Thailand Chong,H. Saokaew,S. Dumrongprat,K. Permsuwan,U. Wu,D.B.C. Sritara,P. Chaiyakunapruk,N. Hematology © 2014 Elsevier Ltd. All rights reserved. Introduction Pharmacogenetic (PGx) test is a useful tool for guiding physician on an initiation of an optimal warfarin dose. To implement of such strategy, the evidence on the economic value is needed. This study aimed to determine the cost-effectiveness of PGx-guided warfarin dosing compared with usual care (UC). Methods A decision analytic model was used to compare projected lifetime costs and quality-adjusted life years (QALYs) accrued to warfarin users through PGx or UC for a hypothetical cohort of 1,000 patients. The model was populated with relevant information from systematic review, and electronic hospital-database. Incremental cost-effectiveness ratios (ICERs) were calculated based on healthcare system and societal perspectives. All costs were presented at year 2013. A series of sensitivity analyses were performed to determine the robustness of the findings. Results From healthcare system perspective, PGx increases QALY by 0.002 and cost by 2,959 THB (99 USD) compared with UC. Thus, the ICER is 1,477,042 THB (49,234 USD) per QALY gained. From societal perspective, PGx results in 0.002 QALY gained, and increases costs by 2,953 THB (98 USD) compared with UC (ICER 1,473,852 THB [49,128 USD] per QALY gained). Results are sensitive to the risk ratio (RR) of major bleeding in VKORC1 variant, the efficacy of PGx-guided dosing, and the cost of PGx test. Conclusion Our finding suggests that PGx-guided warfarin dosing is unlikely to be a cost-effective intervention in Thailand. This evidence assists policy makers and clinicians in efficiently allocating scarce resources. 2015-06-16T07:50:26Z 2015-06-16T07:50:26Z 2014-01-01 Article 00493848 2-s2.0-84915826535 10.1016/j.thromres.2014.10.006 http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84915826535&origin=inward http://cmuir.cmu.ac.th/handle/6653943832/38551 Elsevier Limited
institution Chiang Mai University
building Chiang Mai University Library
country Thailand
collection CMU Intellectual Repository
topic Hematology
spellingShingle Hematology
Chong,H.
Saokaew,S.
Dumrongprat,K.
Permsuwan,U.
Wu,D.B.C.
Sritara,P.
Chaiyakunapruk,N.
Cost-effectiveness analysis of pharmacogenetic-guided warfarin dosing in Thailand
description © 2014 Elsevier Ltd. All rights reserved. Introduction Pharmacogenetic (PGx) test is a useful tool for guiding physician on an initiation of an optimal warfarin dose. To implement of such strategy, the evidence on the economic value is needed. This study aimed to determine the cost-effectiveness of PGx-guided warfarin dosing compared with usual care (UC). Methods A decision analytic model was used to compare projected lifetime costs and quality-adjusted life years (QALYs) accrued to warfarin users through PGx or UC for a hypothetical cohort of 1,000 patients. The model was populated with relevant information from systematic review, and electronic hospital-database. Incremental cost-effectiveness ratios (ICERs) were calculated based on healthcare system and societal perspectives. All costs were presented at year 2013. A series of sensitivity analyses were performed to determine the robustness of the findings. Results From healthcare system perspective, PGx increases QALY by 0.002 and cost by 2,959 THB (99 USD) compared with UC. Thus, the ICER is 1,477,042 THB (49,234 USD) per QALY gained. From societal perspective, PGx results in 0.002 QALY gained, and increases costs by 2,953 THB (98 USD) compared with UC (ICER 1,473,852 THB [49,128 USD] per QALY gained). Results are sensitive to the risk ratio (RR) of major bleeding in VKORC1 variant, the efficacy of PGx-guided dosing, and the cost of PGx test. Conclusion Our finding suggests that PGx-guided warfarin dosing is unlikely to be a cost-effective intervention in Thailand. This evidence assists policy makers and clinicians in efficiently allocating scarce resources.
format Article
author Chong,H.
Saokaew,S.
Dumrongprat,K.
Permsuwan,U.
Wu,D.B.C.
Sritara,P.
Chaiyakunapruk,N.
author_facet Chong,H.
Saokaew,S.
Dumrongprat,K.
Permsuwan,U.
Wu,D.B.C.
Sritara,P.
Chaiyakunapruk,N.
author_sort Chong,H.
title Cost-effectiveness analysis of pharmacogenetic-guided warfarin dosing in Thailand
title_short Cost-effectiveness analysis of pharmacogenetic-guided warfarin dosing in Thailand
title_full Cost-effectiveness analysis of pharmacogenetic-guided warfarin dosing in Thailand
title_fullStr Cost-effectiveness analysis of pharmacogenetic-guided warfarin dosing in Thailand
title_full_unstemmed Cost-effectiveness analysis of pharmacogenetic-guided warfarin dosing in Thailand
title_sort cost-effectiveness analysis of pharmacogenetic-guided warfarin dosing in thailand
publisher Elsevier Limited
publishDate 2015
url http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84915826535&origin=inward
http://cmuir.cmu.ac.th/handle/6653943832/38551
_version_ 1681421494156001280